Abstract
Purpose
Dismal glioblastoma (GB) patient outcome calls for the elucidation of further reliable predictors of prognosis. Established “biomarkers,” age and functional status, employed in today’s patient stratification have limits in fingerprinting this heterogeneous tumor entity. We aimed at ascertaining additional prognostic factors that may facilitate patient stratification for surgery.
Methods
A retrospective review of 233 consecutive adult patients operated on for newly diagnosed GB at a single tertiary institution over a 5-year period (2006–2011) was conducted. Modern defined outcome associating factors recorded included demographics (preoperative age, gender, signs, symptoms, comorbidity status quantified by the Charlson comorbidity index (CCI), functional status computed by the Karnofsky performance scale (KPS)), tumor characteristics (size, location, isocitrate dehydrogenase mutation, and O-6-methylguanine-DNA methyltransferase promoter methylation status), and treatment parameters (volumetrically quantified extent of resection and adjuvant therapy). Survival analysis was performed by the Kaplan–Maier method. Influence of variables was evaluated using log-rank test.
Results
Median neuroradiographic evidence of tumor progression was 6 months after surgery (range 0–72). The median overall survival was 9.5 months (range 0–72). Age > 65 years, KPS ≤ 70, and CCI > 3 were significantly associated with both poor OS (each p < 0.0001) and PFS (p < 0.0001, p < 0.001 and p < 0.002), respectively. Also, patients older than 65 years significantly had a CCI > 3 (p < 0.0001).
Conclusions
Our data evidence that aside established prognostic parameters (age and KPS) for GB patient outcome, the CCI additionally significantly impacts outcome and may be employed for preoperative patient stratification.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Asano K, Nakano T, Takeda T, Ohkuma H (2009) Risk factors for postoperative systemic complications in elderly patients with brain tumors. Clinical article. J Neurosurg 111:258–264. doi:10.3171/2008.10.17669
Balducci M et al (2012) Impact of age and co-morbidities in patients with newly diagnosed glioblastoma: a pooled data analysis of three prospective mono-institutional phase II studies. Med Oncol 29:3478–3483. doi:10.1007/s12032-012-0263-3
Buckner JC (2003) Factors influencing survival in high-grade gliomas. Semin Oncol 30:10–14
Chaichana KL, Chaichana KK, Olivi A, Weingart JD, Bennett R, Brem H, Quinones-Hinojosa A (2011) Surgical outcomes for older patients with glioblastoma multiforme: preoperative factors associated with decreased survival. Clinical article. J Neurosurg 114:587–594. doi:10.3171/2010.8.JNS1081
Chambless LB, Parker SL, Hassam-Malani L, McGirt MJ, Thompson RC (2012) Type 2 diabetes mellitus and obesity are independent risk factors for poor outcome in patients with high-grade glioma. J Neurooncol 106:383–389. doi:10.1007/s11060-011-0676-4
Chambless LB, Kistka HM, Parker SL, Hassam-Malani L, McGirt MJ, Thompson RC (2014) The relative value of postoperative versus preoperative Karnofsky performance scale scores as a predictor of survival after surgical resection of glioblastoma multiforme. J Neurooncol. doi:10.1007/s11060-014-1640-x
Chang SM et al (2003) Perioperative complications and neurological outcomes of first and second craniotomies among patients enrolled in the glioma outcome project. J Neurosurg 98:1175–1181. doi:10.3171/jns.2003.98.6.1175
Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383
Chinot OL et al (2014) Bevacizumab plus radiotherapy–temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709–722. doi:10.1056/NEJMoa1308345
Gilbert MR et al (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:699–708. doi:10.1056/NEJMoa1308573
Grabowski MM, Recinos PF, Nowacki AS, Schroeder JL, Angelov L, Barnett GH, Vogelbaum MA (2014) Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma. J Neurosurg. doi:10.3171/2014.7.JNS132449
Hartmann C et al (2013) Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations. Clin Cancer Res 19:5146–5157. doi:10.1158/1078-0432.CCR-13-0017
Hegi ME et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003. doi:10.1056/NEJMoa043331
Hervey-Jumper SL, Berger MS (2014) Role of surgical resection in low- and high-grade gliomas. Curr Treat Options Neurol 16:284. doi:10.1007/s11940-014-0284-7
Johnson MJ, Bland JM, Davidson PM, Newton PJ, Oxberry SG, Abernethy AP, Currow DC (2014) The relationship between two performance scales: New York Heart Association classification and Karnofsky performance status scale. J Pain Symptom Manag 47:652–658. doi:10.1016/j.jpainsymman.2013.05.006
Keles GE, Chang EF, Lamborn KR, Tihan T, Chang CJ, Chang SM, Berger MS (2006) Volumetric extent of resection and residual contrast enhancement on initial surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. J Neurosurg 105:34–40. doi:10.3171/jns.2006.105.1.34
Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, Cavenee WK (2002) The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61:215–225 discussion 226–219
Lacroix M et al (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95:190–198. doi:10.3171/jns.2001.95.2.0190
Louis DN et al (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109. doi:10.1007/s00401-007-0243-4
Malmstrom A et al (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 13:916–926. doi:10.1016/S1470-2045(12)70265-6
Pusch S, Sahm F, Meyer J, Mittelbronn M, Hartmann C, von Deimling A (2011) Glioma IDH1 mutation patterns off the beaten track. Neuropathol Appl Neurobiol 37:428–430. doi:10.1111/j.1365-2990.2010.01127.x
Sanson M et al (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27:4150–4154. doi:10.1200/JCO.2009.21.9832
Shi WM, Wildrick DM, Sawaya R (1998) Volumetric measurement of brain tumors from MR imaging. J Neurooncol 37:87–93
Solheim O, Selbekk T, Jakola AS, Unsgard G (2010) Ultrasound-guided operations in unselected high-grade gliomas—overall results, impact of image quality and patient selection. Acta Neurochir (Wien) 152:1873–1886. doi:10.1007/s00701-010-0731-5
Stupp R et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. doi:10.1056/NEJMoa043330
Stupp R, Brada M, van den Bent MJ, Tonn JC, Pentheroudakis G, Group EGW (2014) High-grade glioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3):93–101. doi:10.1093/annonc/mdu050
van den Bent MJ et al (2011) Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol 12:583–593. doi:10.1016/S1470-2045(11)70057-2
Weller M, Wick W, Hegi ME, Stupp R, Tabatabai G (2010) Should biomarkers be used to design personalized medicine for the treatment of glioblastoma? Future Oncol 6:1407–1414. doi:10.2217/fon.10.113
Wick W et al (2012) Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 13:707–715. doi:10.1016/S1470-2045(12)70164-X
Conflict of interest
We declare that we have no conflict of interest.
Ethical standard
All studies were approved by the institutional ethics committee and were performed in accordance with the ethical standards laid down in the Declaration of Helsinki 1964 and its later amendments. Further, all patients gave their informed consent prior to their inclusion in the study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ening, G., Osterheld, F., Capper, D. et al. Charlson comorbidity index: an additional prognostic parameter for preoperative glioblastoma patient stratification. J Cancer Res Clin Oncol 141, 1131–1137 (2015). https://doi.org/10.1007/s00432-014-1907-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-014-1907-9